Skip to content

VRTX

Vertex Pharmaceuticals Incorporated

Cash flow statement

Cash flow statement
Line, in USDLast 12 months202520242023202220212020201920182017201620152014201320122011201020092008
Operating cash flow3.69B3.63B−0.49B3.54B4.13B2.64B3.25B1.57B1.27B0.84B0.24B−0.37B−0.57B−61M0.27B0.14B−0.64B−0.43B−0.23B
492M438M298M200M205M235M260M75M95M99M57M45M51M51M71M35M38M23M32M
Free cash flow3.20B3.19B−0.79B3.34B3.93B2.41B2.99B1.49B1.17B0.75B0.18B−0.41B−0.62B−0.11B0.20B0.11B−0.67B−0.45B−0.26B
Depreciation and amortization237M210M207M181M148M126M110M107M72M61M61M62M63M48M38M35M30M30M32M
Stock-based compensation669M686M699M581M491M441M430M361M325M293M241M231M178M127M114M118M91M87M58M
Buybacks1.06B2.02B1.18B0.43B01.43B0.54B0.19B0.35B00————————
Free cash flow margin24.7%26.6%−7.2%33.8%44.0%31.8%48.2%35.9%38.5%30.0%10.5%−39.8%−107.6%−9.2%12.9%7.7%−469.8%−442.7%−147.4%